

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 5/03, 5/027, 5/023, 5/062, 5/083, A61K 38/04		A1	(11) International Publication Number: WO 99/37666
			(43) International Publication Date: 29 July 1999 (29.07.99)
(21) International Application Number: PCT/US99/01097		[US/US]; 16 Beresford Road, Chestnut Hill, MA 02146 (US).	
(22) International Filing Date: 19 January 1999 (19.01.99)		(74) Agent: HUGHES, A., Blair; McDonnell, Boehnen, Hulbert & Berghoff, 32nd floor, 300 South Wacker Drive, Chicago, IL 60606 (US).	
(30) Priority Data: 09/013,365 26 January 1998 (26.01.98) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/013,365 (CON) Filed on 26 January 1998 (26.01.98)			
(71) Applicant (for all designated States except US): CV THERAPEUTICS, INC. [US/US]; 3172 Porter Drive, Palo Alto, CA 94304 (US).			
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only): WANG, Lisa [US/US]; 1545 Floribunda Avenue #312, Burlingame, CA 94010 (US). LUM, Robert, T. [US/US]; 781 Barron Avenue, Palo Alto, CA 94306 (US). SCHOW, Steven, R. [US/US]; 204 Mendocino Way, Redwood City, CA 94065 (US). JOLY, Alison [GB/US]; 3205 Monterey Street, San Mateo, CA 94403 (US). KERWAR, Suresh [US/US]; 90 Edgewood Road, Westchester, NY 10562 (US). WICK, Michael, M.		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: α -KETOAMIDE INHIBITORS OF 20S PROTEASOME

(57) Abstract

α -ketoamide compounds useful for treating disorders mediated by 20S proteasome in mammals having structure (I).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SPECIFICATIONTITLE: α -Ketoamide Inhibitors of 20S Proteasome

10

Background of the Invention:

The multicatalytic proteinase or the proteasome is a highly conserved cellular structure that is responsible for the ATP-dependent proteolysis of most cellular proteins (Coux, O., Tanaka, K. and Goldberg, A. 1996 *Ann. Rev. Biochem.* **65**, 801-847). The 20S proteasome contains the catalytic core of the complex and has been crystallized from the archaebacteria *Thermoplasma acidophilum* (Lowe, J., Stock, D., Jap, B., Zwicki, P., Baumeister, W. and Huber, R. 1995 *Science* **268**, 533-539) and from the yeast *Saccharomyces cerevisiae* (Groll, M., Ditzel, L., Lowe, J., Stock, D., Bochtler, M., Bartunik, HD and Huber, R. 1997 *Nature* **386**, 463-471). Unlike the archaebacterial proteasome that primarily exhibits chymotrypsin-like proteolytic activity (Dahlmann, B., Kopp, F., Kuehn, L., Niedel, B., Pfeifer, G. 1989 *FEBS Lett.* **251**, 125-131; Seemuller, E., Lupas, A., Zuw, F., Zwickl, P and Baumeister, W. *FEBS Lett.* **359**, 173, (1995) the eukaryotic proteasome contains at least five identifiable proteolytic activities. Three of these activities are similar in specificity to chymotrypsin, trypsin and peptidylglutamyl peptidase. The two other activities described exhibit a preference for cleavage of peptide bonds on the carboxyl side of branched chain amino acids (BrAAP) and toward peptide bonds between short chain neutral amino acids (SnAAP) (Orlowski, M. 1990 *Biochemistry* **29**, 10289-10297).

25

Although the 20S proteasome contains the proteolytic core, it cannot degrade proteins *in vivo* unless it is complexed with a 19S cap, at either end of its structure, which itself contains multiple ATPase activities. This larger structure is known as the 26S proteasome and will rapidly degrade proteins that have been targeted for degradation by the addition of

5 multiple molecules of the 8.5-kDa polypeptide, ubiquitin (reviewed in Coux, O., Tanaka, K. and Goldberg, A. 1996 *Ann.Rev. Biochem.* 65, 801-847).

A large number of substrate-derived functionalities have been used as potential serine- and thiol protease inhibitors. Several of these motifs have been described as inhibitors to the proteasome. These include the peptide aldehydes (Vinitsky, A., Michaud, C., Powers, J. and
10 Orlowski, M. 1992 *Biochemistry* 31, 9421-9428; Tsubuki, S., Hiroshi, K., Saito, Y., Miyashita, N., Inomata, M., and Kawashima, S. 1993 *Biochem.Biophys.Res.Commun.* 196,1195-1201; Rock, K.I., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D. and Goldberg, A.L. (1994) *Cell* 78, 761-771) N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal (ALLN) and N-acetyl-L-leucinyl-L-leucinyl-methional (LLM) with the most potent inhibitor
15 of this type being N-carbobenzoyl-L-L-leucinyl-L-leucinyl-L-norvalinal (MG115). Other reports have described a series of dipeptide inhibitors that have IC₅₀ values in the 10 to 100 nM range (Iqbal, M., Chatterjee S., Kauer, J.C., Das, M., Messina, P., Freed, B., Biazzo, W and Siman, R. 1995 *I-Med.Chem.* 38, 2276-2277). A series of α -ketocarbonyl and boronic ester derived dipeptides (Iqbal, M., Chatterjee, S., Kauer, J.C., Mallamo, J.P., Messina, P.A., Reiboldt, A. and Siman, R. 1996 *Bioorg. Med-Chem. Lett* 6, 287-290) and epoxyketones (Spattenstein, A., Leban, JJ., Huang, J.J., Reinhardt, K.R., Viveros, O.H., Sigafoos, J. and Crouch, R. 1996 *Tet. Lett.* 37, 1434-1346) have also been described that are potent inhibitors
20 of the proteasome.

A different compound that exhibits specificity in inhibiting proteasome activity is
25 Lactacystin (Fenteany, G., Standaert, R.F., Lane, W.S., Choi, S., Corey, E.J. and Schreiber, S.L. 1995 *Science* 268, 726-731) which is a *Streptomyces* metabolite. This molecule was originally discovered for its ability to induce neurite outgrowth in a neuroblastoma cell line (Omura, S., Matsuzaki, K., Fujimoto, T., Kosuge, K., Furuya, T., Fujita, S. and Nakagawa, A. 1991 *J.Antibiot.* 44, 117-118) and later was shown to inhibit the proliferation of several cell

5 types (Fenteany, G., Standaert, R.F., Reichard, G.A., Corey, E.J. and Schreiber, S.L. 1994
Proc.Nat'l. Acad.Sci.USA 91, 3358-3362).

It is now well established that the proteasome is a major extralysosomal proteolytic system involved in the proteolytic pathways essential for diverse cellular functions such as cell division, antigen processing and the degradation of short-lived regulatory proteins such as 10 oncogene products, cyclins and transcription factors (Ciechanover, A. (1994) *Cell* 79, 13-21; Palombell, V.J., Rando, O.J., Goldberg, A.L. and Maniatis, T. 1994 *Cell* 78, 773-785). For example, the active form of NF- κ B is a heterodimer consisting of a p65 and a p50 subunit. The latter is present in the cytosol as an inactive precursor (p105). The proteolytic processing of p105 to generate p50 occurs via the ubiquitin-proteasome pathway. Additionally, 15 processed p50 and p65 are maintained in the cytosol as an inactive complex bound to the inhibitory protein I κ B. Inflammatory stimuli such as LPS activate NF- κ B by initiating the signalling pathway which leads to the degradation of I κ B. These signals also stimulate the processing of p105 into p50. Thus two proteolytic events, both governed by the ubiquitin-proteasome pathway, are required for signal induced activation of NF- κ B.

20 The observation that ubiquitin-mediated proteasomal proteolysis plays a critical role in the activation of NF- κ B could be exploited clinically by the use of inhibitors directed toward the proteasome. Abnormal activation of NF- κ B followed by the stimulation of cytokine synthesis has been observed in a variety of inflammatory and infectious diseases. Activation 25 of NF- κ B is also essential for angiogenesis and for expression of adhesion molecules (CAMs and selectins), thus proteasome inhibitors may also have utility in the treatment of diseases associated with the vascular system.

It is well documented that the ubiquitin-proteasome pathway is critical for the regulated destruction of cyclins that govern the exit from mitosis and allow cells to progress into the next phase of the cell cycle (Glotzer, M., Murray, A.W. and Kirschner, M.W. (1991)

5 *Nature* 349, 132-138). Thus, inhibiting the degradation of cyclins by using proteasome inhibitors causes growth arrest. Therefore another potential utility of proteasome inhibitors is their use in the treatment of diseases that result from aberrant cell division.

Several classes of peptidic inhibitors of 20S proteasome have been reported in the recent literature. The α -ketoamide group has been used in protease inhibitors for numerous 10 indications. Specifically, a series of α -ketocarbonyl and boronic ester derived dipeptides (Iqbal, M., Chatterjee, S., Kauer, J.C., Mallamo, J.P., Messina, P.A., Reiboldt, A. and Siman, R. 1996 *Bioorg. Med. Chem. Lett* 6, 287-290) have been reported as potent inhibitors of 20S proteasomal function. Derivatives of 3-indolepyruvic acid have been claimed as pharmaceutically active compounds for the treatment of disturbances of the central nervous 15 system (De Luca, et al WO 88/09789) through a mechanism that modulates kynurenic acid levels in the brain.

Even though various compositions have been discovered that inhibit cell proliferation to some degree, there remains a need for more potent compounds that inhibit cell proliferation via the 20S proteasome.

SUMMARY OF THE INVENTION

It is an object of this invention to provide a method for inhibiting cell proliferation in mammals that uses a therapeutically effective amount of a composition heretofore unknown for its cell proliferative inhibition properties.


It is also an object of this invention to provide a method for the treatment of diseases 10 that may be affected by the inhibition of proteasomal function.

Further, it is an object of this invention to provide a method for the treatment of proliferative diseases that operates by inhibiting proteasomal function.

It is another object of this invention to use a therapeutically effective amount of the compositions described herein to inhibit cell proliferative disorders in humans.


15 Yet another object of this invention is the use of a therapeutically effective amount of the compositions described herein to inhibit proteasomal function.

In one embodiment, this invention is a composition of matter having the formula:



wherein X₂ is Ar or Ar-X₃, wherein X₃ is -C=O, or -CH₂CO-, and wherein Ar is phenyl, 20 substituted phenyl, indole, substituted indoles, and any other heteroaryls; R₁, and R₂ are each individually selected from the side chains of the known natural α -amino acids and unnatural amino acids, hydrogen, 1-10 carbon linear and branched alkyl, 1-10 carbon linear and branched substituted alkyl, aryl, substituted aryl, 1-10 carbon linear, branched substituted aryl, alkoxyaryl, 3-8 carbon cycloalkyl, heterocycle substituted heterocycle, heteroaryl and

5 substituted heteroaryl; X_1 is selected from hydroxide, monoalkylamino, dialkylamino, alkoxide, arylkoxide and



10 wherein X₄ is hydroxide, arylamino, monoalkylamino, dialkylamino, alkoxide, or arylalkoxide; and

R₁ is selected from the known natural α -amino acids, unnatural amino acids, hydrogen, 1-10 carbon linear and branched alkyl, 1-10 carbon linear and branched substituted alkyl, aryl, substituted aryl, 1-10 carbon linear and branched substituted aryl, alkoxyaryl, 3-8 carbon cycloalkyl, heterocycle, substituted heterocycle, heteroaryl and substituted heteroaryl.

15 In another embodiment, this invention is a method for inhibiting proteasomal protease factor in mammals comprising administering a therapeutically effective amount of the composition disclosed above to the mammal.


In still another embodiment, this invention is a pharmaceutical composition of matter comprising the composition of claim 1 and one or more pharmaceutical excipients.

5

DESCRIPTION OF THE CURRENT EMBODIMENT

The invention is a method for inhibiting cell proliferation disorders, infectious diseases, and immunological diseases in mammals, and especially in humans, using compositions having the following general formula:

10



where:


15

X_2 is Ar or Ar-X₃, wherein X₃ is -C=O, -CH₂CO-, or (CH₂)_n where n=0-2 and wherein Ar is phenyl, substituted phenyl, indole, substituted indoles, and any other heteroaryl.

20

R₁, and R₂ are each individually selected from the side chains of the known natural α -amino acids and unnatural amino acids: hydrogen, 1-10 carbon linear and branched alkyl, 1-10 carbon linear and branched substituted alkyl, aryl and substituted aryl, 1-10 carbon linear and branched substituted aryl, alkoxyaryl, 3-8 carbon cycloalkyl, heterocycle and substituted heterocycle, or heteroaryl and substituted heteroaryl. R₂ is preferably biaryl or biphenyl. R₁ is preferably isobutyl. X₁ is selected from -OH, mono or dialkylamino, alkoxide, arylkoxide and

25



wherein:

X₄ is -OH, arylamino, mono or dialkylamino, alkoxide, or arylalkoxide; and preferably -OH

10 R₃ is selected from the side chains of known natural α -amino acids and unnatural amino acids, hydrogen, 1-10 carbon linear alkyl and branched alkyl substituents,

1-10 carbon linear and branched substituted alkyl, aryl and substituted aryl, 1-10

15 carbon linear and branched substituted aryl, alkoxyaryl, 3-8 carbon cycloalkyl, heterocycle and substituted heterocycle, or heteroaryl and substituted heteroaryl.

R₃ is preferably CO₂H, CH₂CO₂H, (CH₂)₂CO₂H, Arg, Lys, Asn, Gln, Asp, Glu, Phe, and Nle.

20 The following are definitions for certain terms used herein.

“Halogen” refers to fluorine, bromine, chlorine, and iodine atoms.

“Hydroxyl” refers to the group -OH.

“Thiol” or “mercapto” refers to the group -SH.

25 “alkyl” refers to a cyclic, branched or straight chain, alkyl group of one to ten carbon atoms. This term is further exemplified by such groups as methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl (or 3-methylpropyl), cyclopropylmethyl, i-amyl, n-amyl, n-hexyl and

5 the like.

"Substituted alkyl" refers to lower alkyl as just described including one or more groups such as hydroxyl, thiol, alkylthiol, halogen, alkoxy, amino, amido, carboxyl, cycloalkyl, substituted cycloalkyl, heterocycle, cycloheteroalkyl, substituted cycloheteroalkyl, acyl, carboxyl, aryl, substituted aryl, aryloxy, hetaryl, substituted hetaryl, aralkyl, 10 heteroaralkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, alkyl cycloheteroalkyl, cyano.

These groups may be attached to any carbon atom of the lower alkyl moiety.

"Aryloxy" denotes groups -OAr, where Ar is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl group as defined below.

"Amino" denotes the group NRR', where R and R' may independently be hydrogen, 15 lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined below or acyl.

"Amido" denotes the group -C(O)NRR', where R and R' may independently be hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, substituted hetaryl as defined below.

20 "Carboxyl" denotes the group -C(O)OR, where R may independently be hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, substituted hetaryl and the like as defined.

"Aryl" or "Ar" refers to an aromatic carbocyclic group having at least one aromatic ring (e.g., phenyl or biphenyl) or multiple condensed rings in which at least one ring is 25 aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, or phenanthryl).

"Substituted aryl" refers to aryl optionally substituted with one or more functional groups, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.

5 "Heterocycle" refers to a saturated, unsaturated, or aromatic carbocyclic group having a single ring (e.g., morpholino, pyridyl or furyl) or multiple condensed rings (e.g., naphthpyridyl, quinoxalyl, quinolinyl, indolizinyl or benzo[b]thienyl) and having at least one hetero atom, such as N, O or S, within the ring, which can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido,
10 carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.

"Heteroaryl" or "hetar" refers to a heterocycle in which at least one heterocyclic ring is aromatic. Preferred heteroaryls are phenyl, substituted phenyl, indole and substituted indoles.

15 "Substituted heteroaryl" refers to a heterocycle optionally mono or poly substituted with one or more functional groups, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.

20 "Cycloalkyl" refers to a divalent cyclic or polycyclic alkyl group containing 3 to 15 carbon atoms.
























"Substituted cycloalkyl" refers to a cycloalkyl group comprising one or more substituents with, e.g., halogen, lower alkyl, substituted lower alkyl, alkoxy, alkylthio, acetylene, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.





































25 Examples of compounds that may be useful in the therapeutic methods of this invention, and specifically, useful as inhibitors of proteosomal function, are identified in Table 1 below:
















































































Examples of compounds that may be useful in the therapeutic method of this invention (specifically, useful as inhibitors of proteosomal function) are listed in the table below:
















Table I. Compositions used to inhibit 20S proteosome

#	Ar	X ₂	R ₂	R ₁	X ₁	R ₃	X ₃
1	phenyl	CH ₂ CO			OH		
2	Indole	CH ₂ CO			OH		
3	Indole	CH ₂ CO			PhCH ₂ N		
4	Indole	CO				H	OH
5	Indole	CH ₂ CO				H	OH
6	phenyl	CH ₂ CO				H	OH
7	phenyl	CH ₂ CO				H	PhCH ₂ N
8	Indole	CO				H	PhCH ₂ N
























9	Indole	CH ₂ CO				PhCH ₂ N
10	Indole	CO				OH
11	phenyl	CO				OH
12	phenyl	CO				OH
13	phenyl	CH ₂ CO				OH
14	Indole	CO				OH
15	Indole	CH ₂ CO				OH
16	phenyl	CO				OH
17	Indole	CH ₂ CO				OH
18	Indole	CH ₂ CO				OH

19	Indole	CH_2CO				
20	Indole	CH_2CO				
21	Indole	CH_2CO				
22	Indole	CH_2CO				
23	Indole	CH_2CO				
24	Indole	CH_2CO				
25	Indole	CH_2CO				
26	Indole	CH_2CO				
27	Indole	CH_2CO				
28	Indole	CH_2CO				
29	Indole	CH_2CO				

























30	Indole	CH_2CO																															
31	Indole	CH_2CO																															
32	Indole	CH_2CO																															
33	Indole	CH_2CO																															
34	Indole	CH_2CO							<img alt="Chemical structure 36: Indole-2-carboxylic acid derivative. It has a wavy line at the 7-position of the indole ring."																								

41	Indole	CH ₂ CO				
42	Indole	CH ₂ CO				
43	Indole	CH ₂ CO				
44	Indole	CH ₂ CO				
45	Indole	CH ₂ CO				
46	Indole	CH ₂ CO				
47	Indole	CH ₂ CO				
48	Indole	CH ₂ CO				
49	Indole	CH ₂ CO				
50	Indole	CH ₂ CO				

61	Indole	CH ₂ CO											
62	Indole	CH ₂ CO											
63	Indole	CH ₂ CO											
64	Indole	CH ₂ CO											
65	Indole	CH ₂ CO											
66	Indole	CH ₂ CO											
67	Indole	CH ₂ CO											
68	Indole	CH ₂ CO											
69	Indole	CH ₂ CO											
70	Indole	CH ₂ CO											




















71	Indole	CH_2CO				
72	Indole	CH_2CO				
73	Indole	CH_2CO				
74	Indole	CH_2CO				
75	Indole	CH_2CO				
76	Indole	CH_2CO				
77	Indole	CH_2CO				
78	Indole	CH_2CO				
79	Indole	CH_2CO				
80	Indole	CH_2CO				



























81	Indole	CH_2CO					
82	Indole	CH_2CO					
83	Indole	CH_2CO					
84	Indole	CH_2CO	$\beta\text{-Ala}$				
85	Indole	CO					
86	Indole	CH_2CO					
87	Indole	CH_2CO					
88	Indole	CH_2CO					
89	Indole	CH_2CO					
90	Indole	CH_2CO	$\beta\text{-Ala}$				

91	Indole	CH ₂ CO				
92	Indole	CH ₂ CO				
93	Indole	CH ₂ CO				
94	Indole	CH ₂ CO				
95	Indole	CH ₂ CO				
96	Indole	CH ₂ CO				
97	Indole	CH ₂ CO				
98	Indole	CH ₂ CO				
99	Indole	CH ₂ CO				
100	Indole	CH ₂ CO				
101	Indole	CH ₂ CO				








































102	Indole	CH_2CO				
103	Indole	CH_2CO				
104	Indole	CH_2CO				
105	Indole	CH_2CO				
106	Indole	CH_2CO				
107	Indole	CH_2CO				
108	Indole	CH_2CO				
109	Indole	CH_2CO				
110	Indole	CH_2CO				
111	Indole	CH_2CO				



















112	Indol	CH_2CO	Nva				OH
113	Indole	CH_2CO					OH
114	Indole	CH_2CO					OH
115	Indole	CH_2CO					OH
116	Indole	CH_2CO					OH
117	Indole	CH_2CO					OH
118	Indole	CH_2CO					OH
119	Indole	CH_2CO	H				OH
120	Indole	CH_2CO	$\beta\text{-Ala}$				OH
















121	Indole	CH_2CO				
122	Indole	CH_2CO				
123	Indole	CH_2CO				
124	Indole	CH_2CO				
125	Indole	CH_2CO				
126	Indole	CH_2CO				
127	Indole	CH_2CO				
128	Indole	CH_2CO				
129	Indole	CH_2CO				





























130	Indole	CH ₂ CO				
131	Indole	CH ₂ CO				
132	Indole	CH ₂ CO				
133	Indole	CH ₂ CO				
134	Indole	CH ₂ CO				
135	Indole	CH ₂ CO				
136	Indole	CH ₂ CO				
137	Indole	CH ₂ CO				
138	Indole	CH ₂ CO				
139	Indole	CH ₂ CO				

140	Indole	CH ₂ CO	<chem>CC(=O)C[C@H]1CCCC(C)C1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	OH
141	Indole	CH ₂ CO	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	OH
142	Indole	CH ₂ CO	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	OH
143	Indole	CH ₂ CO	<chem>CC(C)C[C@H](CCCC(=O)O)c1ccc(O)cc1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)c1ccc(O)cc1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)c1ccc(O)cc1</chem>	OH
144	Indole	CH ₂ CO	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	OH
145	Indole	CH ₂ CO	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C1CCCC(C)C1</chem>	OH
146	Indole	CH ₂ CO	<chem>CC(C)C[C@H](CCCC(=O)O)c1ccccc1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)c1ccccc1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)c1ccccc1</chem>	OH
147	Indole	CH ₂ CO	<chem>CC(C)C[C@H](CCCC(=O)O)c1cccnc1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)c1cccnc1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)c1cccnc1</chem>	OH
148	Indole	CH ₂ CO	<chem>CC(C)C[C@H](CCCC(=O)O)c1ccc2ccccc2c1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)c1ccc2ccccc2c1</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)c1ccc2ccccc2c1</chem>	OH
149	Indole	CH ₂ CO	<chem>CC(C)C[C@H](CCCC(=O)O)C</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C</chem>	OH
150	Indole	CH ₂ CO	<chem>CC(C)C[C@H](CCCC(=O)O)C(=O)C</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C(=O)C</chem>	<chem>CC(C)C[C@H](CCCC(=O)O)C(=O)C</chem>	OH

151	Indole	CH ₂ CO				
152	Indole	CH ₂ CO				
153	Indole	CH ₂ CO				
154	Indole	CH ₂ CO				
155	Indole	CH ₂ CO				
156	Indole	CH ₂ CO				
157	Indole	CH ₂ CO				
158	Indole	CH ₂ CO				
159	Indole	CH ₂ CO				
160	Indole	CH ₂ CO				
161	Indole	CH ₂ CO				



162	Indole	CH ₂ CO				OH
163	Indole	CH ₂ CO				OH
164	Indole	CH ₂ CO				OH
165	Indole	CH ₂ CO				OH
167	Indole	CH ₂ CO				OH
168	Indole	CH ₂ CO				OH
169	Indole	CH ₂ CO				OH
170	Indole	CH ₂ CO				OH

171	Indole	CH_2CO				
172	Indole	CH_2CO				
173	Indole	CH_2CO				
174	Indole	CH_2CO				
175	Indole	CH_2CO				
176	Indole	CH_2CO				
177	Indole	CH_2CO				
178	Indole	CH_2CO				

179	Indole	CH_2CO				
180	Indole	CH_2CO				
181	Indole	CH_2CO				
182	Indole	CH_2CO				
183	Indole	CH_2CO				
184	Indole	CH_2CO				
185	Indole	CH_2CO				
186	Indole	CH_2CO				

187	Indole	CH ₂ CO				
188	Indole	CH ₂ CO				
189	Indole	CH ₂ CO				
190	Indole	CH ₂ CO				
191	Indole	CH ₂ CO				
192	Indole	CH ₂ CO				
193	Indole	CH ₂ CO				

194	Indole	CH ₂ CO				OH
195	Indole	CH ₂ CO				OH
196	Indole	CH ₂ CO				OH
197	Indole	CH ₂ CO				OH
198	Indole	CH ₂ CO				OH
199	Indole	CH ₂ CO				OH
200	Indole	CH ₂ CO				OH
201	Indole	CH ₂ CO				OH

202	Indole	CH_2CO				
203	Indole	CH_2CO				
204	Indole	CH_2CO				
205	Indole	CH_2CO				
206	Indole	CH_2CO				
207	Indole	CH_2CO				
		$\beta\text{-Alanine}$		$\beta\text{-Alanine}$		OH

5 The compounds described above are useful for treating diseases and disorders mediated by the 20S proteasome such as antiproliferative diseases, cancer, inflammation. It is preferred that the compositions of this invention are used to treat antiproliferative disorders and inflammation. It is most preferred that the compounds of this invention are used to treat inflammatory diseases.

10 The compounds of the present invention are useful for treating disorders mediated by 20S proteasome in mammals.

The compounds of this invention may be administered to mammals both prophylactically and therapeutically by any administration protocol that is capable of supplying at least one compound of this invention to a 20S proteasome. Non-limiting examples of useful administration protocols include orally, parenterally, dermally, transdermally, rectally, nasally or by any other suitable pharmaceutical composition administration protocol that is within the knowledge of one skilled in the art.

The compositions of this invention may be administered in suitable pharmaceutical dosage forms. The pharmaceutical dosage form will depend largely upon the administration protocol used. The term pharmaceutical dosage form refers to items such as tablets, capsules, liquids and powders, comprising 20S proteasome inhibitors of this invention alone or in the presence of one or more pharmaceutical excipients. The choice of additives such as excipients and adjuvants again will depend largely upon the chosen administration protocol. Those skilled in the pharmaceutical arts will recognize a wide variety of formulations and vehicles for administering compositions of this invention.

The administration protocol chosen for compounds of this invention will ultimately dictate the final form and composition of pharmaceutical dosage forms comprising the 20S proteasome inhibitors of this invention. For example, internal administration of compounds of this invention is effected, orally, in the form of powders, tablets, capsules, pastes, drinks,

5 granules, or solutions, suspensions and emulsions which can be administered orally, or bolus, in medicated food, or in drinking water. Internal administration may also be accomplished using a timed release formulation including additives such as surfactant or starch coated capsules, or using a quick release formulation such as a freeze-dried fast dissolving tablet. Dermal administration is effected, for example, in the form of transdermal patches, spraying
10 or pouring-on and spotting-on. Parenteral administration is effected, for example, in the form of injection (intramuscularly, subcutaneously, intravenously, intraperitoneally) or by implants.

Suitable pharmaceutical dosage forms incorporating the 20S proteasome inhibitors of this invention include but are not limited to solutions such as solutions for injection, oral solutions, concentrates for oral administration after dilution, solutions for use on the skin or in
15 body cavities, pour-on and spot-on formulations, gels; emulsions and suspension for oral or dermal administration and for injection; semi-solid preparations; formulations in which the active compound is incorporated in cream base or in an oil-in-water or water-in-oil emulsion base; solid preparations such as powders, premixes or concentrates, granules, pellets, tablets, boli, capsules; aerosols and inhalants, and shaped articles containing active compound.

20 Pharmaceutical dosage forms that are solutions may be administered by injection intravenously, intramuscularly and subcutaneously. Solutions for injection are prepared by dissolving the active compound in a suitable solvent and, if appropriate, adding adjuvants such as solubilizers, acids, bases, buffer salts, antioxidants and preservatives. The solutions are sterile-filtered and drawn off.

25 Alternatively, solutions including compositions of this invention may be administered orally. Concentrates of compositions of this invention are preferably administered orally only after diluting the concentrate to the administration concentration. Oral solutions and concentrates are prepared as described above in the case of the solutions for injection. Solutions for use on the skin are applied dropwise, brushed on, rubbed in, splashed on or

5 sprayed on. These solutions are prepared as described above in the case of solutions for injection.

Gels are applied to the skin, or introduced into body cavities. Gels are prepared by treating solutions which have been prepared as described in the case of the solutions for injection with such an amount of thickener that a clear substance of cream-like consistency is
10 formed, or by any other means known to one skilled in the art.

Pour-on and spot-on formulations are poured onto, or splashed onto, limited areas of the skin, the active compound penetrating the skin and acting systemically. Pour-on and spot-on formulations are prepared by dissolving, suspending or emulsifying the active compound in suitable solvents or solvent mixtures which are tolerated by the skin. If appropriate, other
15 adjuvants such as colorants, resorption accelerators, antioxidants, light stabilizers, and tackifiers are added.

Emulsions can be administered orally, dermally or in the form of injections. Emulsions are either of the water-in-oil type or of the oil-in-water type. They are prepared by dissolving 20S proteasome inhibitors either in the hydrophobic or in the hydrophilic phase
20 and homogenizing the phase with a solvent of the opposite phase with the aid of suitable adjuvants such as emulsifiers, colorants, resorption accelerators, preservatives, antioxidants, light stabilizers, and viscosity-increasing substances.

Suspensions can be administered orally, dermally or in the form of injection. They are prepared by suspending the active compound in a liquid if appropriate with the addition of
25 further adjuvants such as wetting agents, colorants, resorption accelerators, preservatives, antioxidants and light stabilizers.

The pharmaceutical compositions of this invention may include one or more additives in the form of pharmaceutically acceptable additives. Useful additives include solvents, solubilizers, preservatives, thickeners, wetting agents, colorants, resorption accelerators,

5 antioxidants, light stabilizers, tackifiers, viscosity increasing substances, fillers, flavorings, lubricating agents, and any other pharmaceutical composition additive known to those skilled in the art.

The additive may be a solvent such as water, alcohols such as ethanol, butanol, benzyl alcohol, glycerol, propylene glycol, polyethylene glycols, N-methyl-pyrrolidone, alkanols, 10 glycerol, aromatic alcohols such as benzyl alcohol, phenylethanol, phenoxyethanol, esters such as ethyl acetate, butyl acetate, benzyl benzoate, ethers such as alkylene glycol alkyl ethers such as dipropylene glycol mono-methyl ether, diethylene glycol mono-butyl ether, ketones such as acetone, methyl ethyl ketone, aromatic and/or aliphatic hydrocarbons, vegetable or synthetic oils, DMF, dimethylacetamide, N-methyl-pyrrolidone, 2,2-dimethyl-4-15 oxy-methylene-1,3-dioxolane.

The following additives may be useful as solubilizers of the compositions of this invention: solvents which enhance solution of the active compound in the main solvent or which prevent its precipitation. Examples are polyvinylpyrrolidone, polyoxyethylated castor oil, polyoxyethylated sorbitan esters.

20 Useful preservatives are, for example, benzyl alcohol, trichlorobutanol, p-hydroxybenzoic esters, and n-butanol.

Useful thickeners include inorganic thickeners such as bentonite, colloidal silica, aluminum monostearate, organic thickeners such as cellulose derivatives, polyvinyl alcohols and their copolymers, acrylates and methacrylates.

25 Other liquids which may be useful in pharmaceutical dosage forms of this invention are, for example, homogeneous solvents, solvent mixtures, and wetting agents which are typically surfactants.

Useful colorants are all colorants which are non-toxic and which can be dissolved or suspended.

5 Useful resorption accelerators are DMSO, spreading oils such as isopropyl myristate, cipropylene glycol pelargonate, silicone oils, fatty acid esters, triglycerides, fatty alcohols.

Useful antioxidants are sulphites or metabisulphites such as potassium metabisulphite, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole, tocopherol.

A useful light stabilizer is novantisolic acid.

10 Useful tackifiers include cellulose derivatives, starch derivatives, polyacrylates, natural polymers such as alginates, gelatin.

Useful emulsifiers include non-ionic surfactants such as polyoxyethylated castor oil, polyoxyethylated sorbitan monooleate, sorbitan monostearate, glycerol monostearate, polyoxyethyl stearate, alkylphenol polyglycol ethers; amphotolytic surfactants such as Di-Na N-15 lauryl- beta -iminodipropionate or lecithin; anionic surfactants, such as Na-lauryl sulphate, fatty alcohol ether sulphates, the monoethanolamine salt of mono/dialkylpolyglycol ether orthophosphoric esters; cationic surfactants such as cetyltrimethylammonium chloride.

Useful viscosity-increasing substances and substances which stabilize a therapeutic emulsion include carboxymethylcellulose, methylcellulose and other cellulose and starch derivatives, polyacrylates, alginates, gelatin, gum Arabic, polyvinylpyrrolidone, polyvinyl alcohol, copolymers of methyl vinyl ether and maleic anhydride, polyethylene glycols, waxes, colloidal silica or mixtures of the substances mentioned.

To prepare solid pharmaceutical dosage forms, the active compound is mixed with suitable additives, if appropriate with the addition of adjuvants, and the mixture is formulated 25 as desired. Examples of physiologically acceptable solid inert additives include sodium chloride, carbonates such as calcium carbonate, hydrogen carbonates, aluminum oxides, silicas, clays, precipitated or colloidal silicon dioxide, and phosphates. Examples of solid organic additives include sugars, cellulose, foods such as dried milk, animal meals, cereal meals and coarse cereal meals and starches. Other suitable additives include lubricants and

5 gliding agents such as magnesium stearate, stearic acid, talc, bentonites; disintegrants such as starch or crosslinked polyvinylpyrrolidone; binders such as, starch, gelatin or linear polyvinylpyrrolidone; and dry binders such as microcrystalline cellulose.

In the pharmaceutical dosage forms described herein, the active compounds can be present in the form of a mixture with at least one other 20S proteasome inhibitor.

10 Alternatively, or in addition, the pharmaceutical dosage forms of the invention can, in addition to at least one 20S proteasome inhibitor, include any pharmaceutical compound that is capable of treating any known malady or disorder where the administration of both together create no unacceptable adverse effects.

Methods for treating 20S proteasome mediated diseases and disorders comprises the 15 administration of an effective quantity of the chosen compound or combinations thereof, preferably dispersed in a pharmaceutical dosage form. Ready-to-use pharmaceutical dosage forms of this invention contain the active compound in concentrations of from 10 ppm to 20 per cent by weight; and preferably of from 0.1 to 10 per cent by weight. Pharmaceutical dosage forms of this invention that are diluted prior to administration, preferably contain the 20 active compound in concentrations of from 0.5 to 90 per cent by weight, and preferably of from 5 to 50 per cent by weight. In general, it has proved advantageous to administer amounts of approximately 0.01mg to approximately 100 mg of active compound per kg of body weight per day to achieve effective results.

The amount and frequency of administration of pharmaceutical dosage forms 25 comprising 20S proteasome inhibitors of this invention will be readily determined by one skilled in the art depending upon, among other factors, the route of administration, age and condition of the patient. These dosage units may be administered one to ten times daily for acute or chronic disease. No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.

5 The pharmaceutical dosage forms comprising 20S proteasome inhibitors of this invention are made following the conventional techniques of pharmacy involving milling, mixing, granulation, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. When a liquid additive is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous
10 suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.

While the compositions described herein may be administered as described above, it is preferred that the method of this invention is achieved by administering the compound described herein orally. When the oral administration route is chosen, a larger quantity of
15 reactive agent will be required to produce the same effect as a smaller quantity given for example parenterally. In accordance with good clinical practice, it is preferred to administer the compound according to this method at a concentration level that would produce effective therapeutic results without causing any harmful side effects.

The compositions of this invention have non-therapeutic utility as well. The
20 compositions of this invention are useful as analytical standards for 20S proteasome inhibitor assays.

Example 1

The compounds useful in the therapeutic method of this invention are prepared by conventional methods of organic chemistry. References that may be consulted in describing the art of the synthesis of these compounds include Bodansky's "The Practice of Peptide Synthesis," Springer-Verlag, First Edition, 1984; "Protective Groups in Organic Synthesis," 10 Second Edition, John Wiley and Sons, New York, 1991. All peptide couplings are accomplished at room temperature with gentle and constant agitation. Peptide couplings and deprotections are monitored using the Kaiser test for amines. Xaa refers to any of the commercially available amino acids that may be purchased pre-attached to the MBHA resin.

15 Yaa and Zaa refer to any of the commercially available amino acids.

The compounds of this invention may be prepared by solid phase peptide synthesis (SPPS) in the general procedure that follows: Xaa-MBHA-resin is weighed and transferred to a syringe equipped with a fritted filter. The resin is pre-swollen in DMF and then the N-terminal protecting group is removed by treatment with 30%, piperidine in DMF for 30 minutes. The deprotection solution is removed. The deprotected resin is washed five times with DMF, five times with MeOH, and then five times with DMF. Amino acid Yaa may then be coupled to the deprotected resin using a solution of Yaa in DMF containing 3 equivalents each of Yaa, carbodiimide coupling reagent and HOBT (hydroxy benzotriazole). Successive couplings with solutions of Yaa may be necessary to achieve coupling efficiencies that pass the Kaiser test. The N-terminal group deprotection and Yaa coupling step may be repeated to couple a third amino acid Zaa. The final coupling step uses ketoacid, carbodiimide, and HOBT in DMF, and this step is repeated until the coupling passes the Kaiser test. The completed peptide sequence on resin is dried under vacuum for at least six hours and then cleaved by treatment for 2.5 hours with either 95/5 trifluoroacetic acid/water or a freshly prepared solution of 90%, trifluoroacetic acid, 3% ethanedithiol, 5% thioanisole, and 2%

5 anisole. The cleaved products are recovered by either lyophilization from water or trituration from diethyl ether. Product purities are estimated from TLC. Selected peptide samples are checked by ^1H NMR to confirm product identity.

Example 2

In this Example (3'-Indolepyruvic acid)- N-biphenylalanine-D-Leu-Asp-OH was prepared according to the method of Example 1.

Fmoc-N-Asp(*O*-Bu)-MBHA-resin (20 mg) is weighed and transferred to a syringe equipped with a fritted filter. The resin is pre-swollen in 1 mL DMF for 30 minutes. The Fmoc (fluorenylmethyloxycarbonyl) protecting group is removed by treatment with 20% piperidine in DMF for 30 minutes. The deprotection solution is removed. The deprotected resin is washed five times with DMF, five times with MeOH, and then five times with DMF. Fmoc-D-Leu-OH is coupled to the deprotected resin (1 eq) using a solution of Fmoc-D-Leu-OH (3 eq) in 1 mL DMF containing carbodiimide (3 eq) and HOBT (hydroxy benzotriazole) (3 eq). A second or third coupling with solutions of Fmoc-D-Leu-OH may be necessary to achieve coupling efficiencies that pass the Kaiser test. The Fmoc deprotection and amino acid coupling step are repeated to couple Fmoc-N- (4,4-biphenyl)alanine. The final coupling step uses indolepyruvic acid (5eq), diisopropylcarbodiimide (5eq), and HOBT (5eq) in DMF, and this step is repeated until the coupling passes the Kaiser test. The completed peptide sequence on resin is dried under vacuum for at least six hours and then cleaved by treatment for 2.5 hours with 1 mL of either 95/5 trifluoroacetic acid/water or a freshly prepared solution of 90% trifluoroacetic acid, 5% thioanisole, 3% ethanedithiol, and 2% anisole. The cleaved products are recovered by either lyophilization from water or trituration from diethyl ether. Product purities are estimated from TLC.

¹H NMR (400 MHz, d₆-DMSO): δ 6.5-7.7 (m, 14H), 4.5 (m, 1H), 4.1(m, 2H), 3.4(m, 2H), 3 (m, H), 2.7 (m, 1H), 1.1-1.5 (m, 3H), 0.5-0.9 (m, 6H).

5

Example 3

In this example, (3'-Indolepyruvic acid)-N-biphenylalaanine-D-Leu-Asp-OH was prepared using Chiron Mimotopes Pin Technology

The first amino acid residue Xaa is attached to 4-(hydroxymethyl)phenoxyacetamido handle) resin pins (5.7 μ mole/pin) by coupling each pin in 800 μ L of coupling solution (100 mM amino acid, 100 mM DIC, 10 mM DMAP, 1/4 DMF/CH₂Cl₂) for two hours. The pins are then rinsed with a 5 min DMF wash, two 5 min MeOH washes, and 15 minutes of air drying. Deprotection of the Fmoc group is carried out for 30 min with 800 μ L 20% piperidine in DMF. Repeat pin washings (1 DMF wash, 2 MEOH washes, 15 minutes air drying). The second amino acid residue Yaa was coupled (100 mM Yaa, 100 mM DIC, 100 mM HOBT, and bromophenol blue indicator in DMF) until the blue color no longer adheres to the pin surface. The coupling was repeated as necessary. The rinse cycle and Fmoc deprotection washes were then repeated as well. The next amino acid, Zaa, was coupled by repeating the coupling and washing procedures for coupling Yaa, repeating the coupling if necessary. The last residue, indolepyruvic acid is coupled with 15 eq, 100 mM, 15 eq DIC, 15 eq HOBT, and bromophenol blue indicator in DMF. Repeat coupling if necessary. After the last wash, the orange pins were removed from their supports and cleaved in individual 2 mL plastic centrifuge tubes with 1.5 mL of a freshly prepared solution of 90%, trifluoroacetic acid, 5% thioanisole, 3% ethanedithiol, and 2% anisole for 2.5 hours. The pins were removed from the tubes and the mixture was blown to near dryness under a nitrogen stream. Triturate with Et₂O and spin down each tube. This step was repeated three times per tube. The precipitated peptides were collected, lyophilized, weighed, and used. Product purity was estimated by TLC. Initial products were cospotted and checked against authentic samples obtained in Example 1.

Example 4

Compounds of this invention prepared according to the method of Example 1 were tested as follows. The 20S catalytic subunit of the proteasome (also known as the multicatalytic proteinase complex) was purified to homogeneity from bovine brain according to published methods (Wilk S. and Orlowski,M 1983, 40 842 J.Neurochem). The chymotryptic activity of the complex is measured by the increase in fluorescence following cleavage of the substrate peptide succinyl-leucine-leucine-valine-tyrosine-7-amino-4methyl coumarin. The standard *in vitro* assay consists of 2 μ g 20S proteasome, 0.1-100 μ g/ml proteasome inhibitor in 200 μ l 50mM HEPES, containing 0.1% sodium dodecyl sulphate, pH7.5. The proteolytic reaction is initiated by the addition of 50 μ M flourogenic peptide substrate and allowed to progress for 15 minutes at 37°C. The reaction is terminated by the addition of 100 μ L of 100 mM acetate buffer, pH4.0. The rate of proteolysis is directly proportional to the amount of liberated aminomethylcoumarin which is measured by fluorescent spectroscopy (EX 370nm, EM 430nm).

The results of the 20S proteasome inhibitor assays are presented in Table II.

Table II.

IC 50 values for the inhibition of the chymotrypsin-like activity of 20S proteasome.

Compound #	IC ₅₀ μ g/mL	Compound #	IC ₅₀ μ g/mL
1	10	105	>10
2	10	106	>10
3	>10	107	>10
4	10	108	>10
5	>10	109	>10
6	>10	110	>10
7	>10	111	>10
8	>10	113	>10
9	>10	114	10
10	>10	115	10
11	>10	116	10

5

Compound #	IC ₅₀ µg/mL	Compound #	IC ₅₀ µg/mL
12	>10	117	10
13	>10	118	10
14	>10	119	>10
15	10	120	>10
16	10	121	>10
17	>10	122	>10
18	>10	123	>10
19	>10	124	>10
20	>10	125	>10
21	>10	126	>10
22	>10	127	>10
23	>10	128	>10
24	>10	129	10
25	>10	130	10
26	>10	131	10
27	>10	132	10
28	>10	133	10
29	>10	134	>10
30	>10	135	>10
31	>10	136	>10
32	>10	137	>10
33	>10	138	>10
34	>10	139	>10
35	>10	140	>10
36	>10	141	>10
37	>10	142	>10
38	>10	143	>10
39	>10	144	10
40	>10	145	10
41	>10	146	10
42	>10	147	10
43	>10	148	10
44	>10	149	10
45	>10	150	>10
46	>10	151	>10
47	>10	152	>10
48	>10	153	>10
49	>10	154	>10
50	>10	155	>10
51	>10	156	>10
52	>10	157	>10
53	>10	158	>10
54	>10	159	>10
55	>10	160	>10

Compound #	IC ₅₀ µg/mL	Compound #	IC ₅₀ µg/mL
56	>10	161	>10
57	>10	162	>10
58	>10	163	>10
59	>10	164	>10
60	>10	165	>10
61	>10	166	>10
62	>10	167	>10
63	>10	168	>10
64	>10	169	>10
65	>10	170	>10
66	>10	171	>10
67	>10	172	>10
68	>10	173	>10
69	>10	174	5
70	>10	175	>10
71	>10	176	1
72	>10	177	10
73	>10	178	>10
74	>10	179	>10
75	>10	180	5
76	>10	181	10
77	>10	182	>10
78	>10	183	10
79	>10	184	>10
80	>10	185	5
81	>10	186	>10
82	>10	187	>10
83	>10	188	5
84	>10	189	>10
85	>10	190	3
86	>10	191	3
87	>10	192	3
88	>10	193	>10
89	>10	194	>10
90	>10	195	>10
91	>10	196	>10
92	>10	197	10
93	>10	198	>10
94	>10	199	>10
95	>10	200	>10
96	>10	201	>10
97	>10	202	>10
98	>10	203	>10
99	>10	204	>10

5

Compound #	IC_{50} $\mu\text{g/mL}$	Compound #	IC_{50} $\mu\text{g/mL}$
100	>10	205	>10
101	>10	206	>10
103	>10	207	10
104	>10		

Compounds of this invention prepared according to the method of Example 1 were also tested as follows. The 20S catalytic subunit of the proteasome (also known as the multicatalytic proteinase complex) was purified to homogeneity from bovine brain according 10 to published methods (Wilk S. and Orlowski, M 1983, 40 842 J. Neurochem). The tryptic activity of the complex is measured by the increase in fluorescence following cleavage of the substrate peptide CBZ-D-Ala-Leu-Arg-(7-amino -4-methyl coumarin). The standard *in vitro* assay consists of 2 μg 20S proteasome, 0.1-100 $\mu\text{g}/\text{ml}$ proteasome inhibitor in 200ml 50mM HEPES, containing 0.1% sodium dodecyl sulphate, pH 7.5. The proteolytic reaction is 15 initiated by addition of 50mM flurogenic peptide substrate and allowed to progress for 15 minutes at 37°C. The reaction is terminated by the addition of 100 mL of 100 mM acetate buffer, pH4.0. The rate of proteolysis is directly proportional to the amount of liberated aminomethylcoumarin which is measured by fluorescent spectroscopy (EX 370nm, EM 430nm). Compounds 1-207 were tested for tryptic activity inhibition and active as inhibitors 20 at >10 $\mu\text{g}/\text{mL}$.

5

Example 5

Compounds of this invention prepared according to the method of Example 1 were also tested as follows. The 20S catalytic subunit of the proteasome (also known as the multicatalytic proteinase complex) was purified to homogeneity from bovine brain according to published methods (Wilk S. and Orlowski, M. 1983, 40 842 J. Neurochem). The tryptic activity of the complex is measured by the increase in fluorescene following cleavage of the substrate peptide CBZ D-Ala-Leu-Arg-(7-amino-4-methyl coumarin). The standard *in vitro* assay consists of 20 µg 20S proteasome, 0.1-100µg/ml proteasome inhibitor in 200 µL 50mM HEPES, containing 0.1% sodium dodecyl sulphate, pH 7.5. The proteolytic reaction is initiated by the addition of 50mM fluorogenic peptide substrate and allowed to progress for 15 minutes at 37°C. The reaction is terminated by the addition of 100 µL of 100 mM acetate buffer, pH4.0. The rate of proteolysis is directly proportional to the amount of liberated aminomethylcoumarin which is measured by flurosecent spectroscopy (EX 370nm, EM 430nm). Compounds 1-207 were tested for tryptic activity inhibition and were active as inhibitors at > 10 µg/mL.

20

5

Example 6


Compounds of this invention prepared according to the method of Example 1 were also tested as follows. The 20S catalytic subunit of the proteasome (also known as the multicatalytic proteinase complex) was purified to homogeneity from bovine brain according to published methods (Wilk S. and Orlowski, M. 1983, 40 842 J. Neurochem). The tryptic activity of the complex is measured by the increase in fluorescence following cleavage of the substrate peptide CBZ D-Ala-Leu-Glu-(7-amino-4-methyl coumarin). The standard *in vitro* assay consists of 2 µg 20S proteasome, 0.1-100µg/ml proteasome inhibitor in 200ml 50mM HEPES, containing 0.1% sodium dodecyl sulphate, pH 7.5. The proteolytic reaction is initiated by the addition of 50mM fluorogenic peptide substrate and allowed to progress for 15 minutes at 37°C. The reaction is terminated by the addition of mL of 100 mM acetate buffer, pH 4.0. The rate of proteolysis is directly proportional to the amount of liberated aminomethylcoumarin which is measured by fluorescent spectroscopy (EX 370nm, EM 430nm). Compounds 1-207 were tested for peptidylglutamyl activity inhibition at > 10 µg/mL. Compound 190 was active at 5 µg/mL.

20

5

What we claim is:

1. A compound having the formula:




wherein:

10 X_2 is Ar or Ar-X₃, wherein X₃ is -C=O, -CH₂CO-, or (CH₂)_n where n=0-2, and wherein Ar is phenyl, substituted phenyl, indole, substituted indoles, and any other heteroaryls;

15 R₁, and R₂ are each individually selected from side chains of the known natural α -amino acids and unnatural amino acids, hydrogen, 1-10 carbon linear and branched alkyl, 1-10 carbon linear and branched substituted alkyl, aryl, substituted aryl, 1-10 carbon linear, branched substituted aryl, alkoxyaryl, 3-8 carbon cycloalkyl, heterocycle substituted heterocycle, heteroaryl and substituted heteroaryl.

20 X₁ is selected from -OH, monoalkylamino, dialkylamino, alkoxide, arylkoxide and




20

wherein:

5 X_4 is hydroxide, arylamino, monoalkylamino, dialkylamino, alkoxide, or
arylalkoxide;

R₁ is selected from the side chains of known natural α -amino acids, unnatural amino acids, hydrogen, 1-10 carbon linear and branched alkyl, 1-10 carbon linear and branched substituted alkyl, aryl, substituted aryl, 1-10 carbon linear and branched substituted aryl, 10 alkoxyaryl, 3-8 carbon cycloalkyl, heterocycle, substituted heterocycle, heteroaryl and substituted heteroaryl.

2. The composition of claim 1 wherein X₁ is



15 3. The composition of claim 2 wherein X₄ is -OH.

4. The composition of claim 1 wherein X₄ is -OH.

5. The composition of claim 4 wherein R₁ is selected from 1-10 carbon branched alkyl, and 1-10 carbon unbranched alkyl substituents.

6. The composition of claim 1 wherein X₄ is -OH, and R₁ and R₂ are each individually selected from side chains of the known natural α -amino acids, unnatural amino acids, and 1-10 carbon linear, alkyl and branched alkyl substituents.

7. The composition of claim 6 wherein X₃ is selected from -C=O, -CH₂CO-, and (-CH₂)_n wherein n=0-2.

8. The composition of claim 7 wherein R₁ is selected from CO₂H, CH₂CO₂H, (CH₂)₂CO₂H, Arg, Lys, Asn, Gln, Asp, Glu, Phe and Nle.

5 9. The composition of claim 8 wherein Ar is selected from indole and substituted indole.

10 10. The composition of claim 8 wherein Ar is selected from phenyl and substituted phenyl.

11 11. The composition of claim 1 wherein X₂ is CH₂CO and R₁ is isobutyl.

10 12. The composition of claim 11 wherein X₂ is -OH, R₃ is H, X₃ is H and Ar is selected from the group consisting of phenyl and indole.

13. The composition of claim 11 wherein Ar is indole, R₁ is D-Leu (isobutyl), X₁ is H, and X₃ is -OH.

14. The composition of claim 13 wherein R₂ is 2-NAP and R₃ is Asp.

15 15. The composition of claim 13 wherein R₂ is 4,4'-BPA and R₃ is selected from the group consisting of Nle, Asp, Asn, β-Alanine, His, and Arg.

16. The composition of claim 1 wherein Ar is indole, X₃ is selected from -C=O, and CH₂CO, R₃ is selected from biaryl and substituted biphenyl, R₁ is isobutane, R₂ is CH₂CO₂H and X₄ is -OH.

20 17. The composition of claim 1 wherein Ar is selected from phenyl and substituted phenyl, X₃ is selected from -C=O and -CH₂CO, R₂ is selected from biaryl and biphenyl, R₁ is isobutyl, R₃ is CH₂CO₂H, and X₄ is -OH.

18. The composition of claim 1 wherein Ar is indole, X₃ is CH₂CO, R₂ is 4,4'-biphenyl, R₁ is isobutyl, R₃ is CH₂CO₂H, and X₄ is -OH.

25 19. A cationic salt of the composition of claim 1.

20. An acid addition salt of the composition of claim 1.

21. A method for inhibiting cancer in mammals comprising administering a therapeutically effective amount of the composition of claim 1 to the mammal.

5 22. The method of claim 21 wherein the therapeutically effective amount ranges from about 0.001 to about 100 mg/kg weight of the mammal.

10 23. The method of claim 21 wherein the composition is administered to a mammal suffering from auto immune disorders selected from the group consisting of lupus, MS, ARD and arthritis.

15 24. The method of claim 23 wherein the disorder is RA.

25. The method of claim 21 wherein the mammal is a human.

26. A pharmaceutical composition of matter comprising the composition of claim 1 and one or more pharmaceutical excipients.

27. The pharmaceutical composition of matter of claim 26 wherein the pharmaceutical composition is in the form of a solution.

28. The pharmaceutical composition of matter of claim 26 wherein the pharmaceutical composition is in the form of a tablet.

INTERNATIONAL SEARCH REPORT

Inte onal Application No
PCT/US 99/01097

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K5/03 C07K5/027 C07K5/023 C07K5/062 C07K5/083
A61K38/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 656 604 A (HEMMI KEIJI ET AL) 12 August 1997 The whole document; see especially examples 79,81,153,155 ----	1-10, 19, 26-28
X	DA SETTIMO A ET AL: "Synthesis and benzodiazepine receptor affinity of N-(indol-3-ylglyoxylyl)-dipeptide derivatives. Structural requirements for inverse agonist/antagonist receptor interactions" DRUG DES. DISCOVERY (DDDIEV, 10559612); 1993; VOL.10 (3); PP.199-211, XP002103282 Univ. Pisa; Ist. Chim. Farm.; Pisa; 56126; Italy (IT) see the whole document ----	1, 26-28

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 May 1999	04/06/1999
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer Groenendijk, M

INTERNATIONAL SEARCH REPORT

Inte	onal Application No
PCT/US 99/01097	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 468 339 A (NIPPON KAYAKU KK) 29 January 1992 See especially Table 1 ---	1,26-28
X	CHEMICAL ABSTRACTS, vol. 089, no. 15, 9 October 1978 Columbus, Ohio, US; abstract no. 129909, LARSEN B R ET AL: "Products from the reaction of ninhydrin with triphenylalanine" XP002102781 see abstract & ANAL. BIOCHEM. (ANBCA2,00032697);1978; VOL.86 (1); PP.127-32, Univ. Texas Dent. Branch;Dep. Biochem.; Galveston; Tex. ---	1
A	IQBAL E.A.: "potent inhibitors of proteasome" JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, 1995, pages 2276-2277, XP002102780 WASHINGTON US see the whole document ---	1-28
A	IQBAL M ET AL: "Potent alpha-ketocarbonyl and boronic ester derived inhibitors of proteasome" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 3, 6 February 1996, page 287-290 XP004135079 cited in the application see the whole document ---	1-28
A	WO 88 09789 A (POLIFARMA SPA) 15 December 1988 cited in the application see the whole document ---	1-28
A	WO 95 25533 A (HARVARD COLLEGE) 28 September 1995 see the whole document ---	1-28
A	WO 96 13266 A (PROSCRIPT INC) 9 May 1996 see the whole document ---	1-28
A	WO 95 24914 A (MYOGENICS INC) 21 September 1995 see abstract ---	1-28
P,X	WO 98 13061 A (CV THERAPEUTICS INC ;JOLY ALISON (US); KERWAR SURESH (US); LUM ROB) 2 April 1998 see the whole document ---	1-8, 19-28
		-/-

INTERNATIONAL SEARCH REPORT

Inte	onal Application No
PCT/US 99/01097	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>LUM R T ET AL: "Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 3, 3 February 1998, page 209-214 XP004136850 see the whole document</p> <p>-----</p>	1-7, 11, 19-28

INTERNATIONAL SEARCH REPORT

rnational application No.

PCT/US 99/01097

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 21-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: 1-15, 19-28 (partial)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: 1-15,19-28(all partially)

The scope of the claims 1-15 is very broad and speculative and/or said claims are ambiguous and unclear. A formula consisting virtually of variables which are moreover in at least part of the claims ill-defined (e.g. the use of "aryl", "heteroaryls" and "sidechain of an unnatural amino acid) cannot be considered to be a clear and concise definition of patentable subject-matter (Art.6 PCT).

Furthermore the claims contain a number of inconsistencies and ambiguous definitions:

- 1) from the description it appears that the application relates to -ketoamides whereas claim 1 also encompasses compounds lacking said structural entity (compounds wherein X3 is $(CH_2)_n$);
- 2) in the claims 8, 14 and 15 (part of) the sidechains appear to consist of amino acid residues;
- 3) in claim 11 X2 has been defined as X3;
- 4) In the claims 12 and 13 the definitions of X2 and X3 are incompatible with claim 1.

Therefore a meaningful and economically feasible search could not encompass the complete subject-matter of the claims. Consequently the search had been directed to the claims 16-18 and the compounds defined in the examples (wherein X2 has been read as being X3) (closely) and also the claims 19-28 as far as relating to said compounds (Art.17(2)(a)(ii) and (b) PCT, PCT Guidelines CIII,2.1 and CIII,3.7).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/01097

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5656604	A 12-08-1997	US 5430022 A		04-07-1995
		AT 165100 T		15-05-1998
		AU 7644691 A		14-11-1991
		CA 2042442 A		15-11-1991
		CN 1057269 A		25-12-1991
		DE 69129248 D		20-05-1998
		DE 69129248 T		06-08-1998
		EP 0457195 A		21-11-1991
		FI 912328 A		15-11-1991
		HU 9500377 A		28-09-1995
		JP 4244097 A		01-09-1992
		PT 97638 A, B		28-02-1992
		RU 2092491 C		10-10-1995
		US 5284828 A		08-02-1994
		JP 6025286 A		01-02-1994
		JP 5208914 A		20-08-1993
EP 0468339	A 29-01-1992	JP 4211648 A		03-08-1992
		DE 69125537 D		15-05-1997
		DE 69125537 T		17-07-1997
		ES 2102989 T		16-08-1997
		US 5221752 A		22-06-1992
		JP 5221967 A		31-08-1993
WO 8809789	A 15-12-1988	AT 86247 T		15-03-1993
		AU 609500 B		02-05-1991
		AU 1943388 A		04-01-1989
		CA 1328658 A		19-04-1994
		DE 3878866 A		08-04-1993
		DK 46789 A		31-03-1989
		EP 0321516 A		28-06-1989
		FI 890508 A, B,		02-02-1989
		JP 2500369 T		08-02-1990
		KR 9616522 B		14-12-1996
		US 5002963 A		26-03-1991
WO 9525533	A 28-09-1995	AU 682264 B		25-09-1997
		AU 2121595 A		09-10-1995
		CA 2184727 A		28-09-1995
		EP 0750507 A		02-01-1997
		JP 9510710 T		28-10-1997
WO 9613266	A 09-05-1996	AU 4139896 A		23-05-1996
		CA 2203936 A		09-05-1996
		CN 1168633 A		24-12-1997
		EP 0788360 A		13-08-1997
		FI 971746 A		06-06-1997
		JP 10510245 T		06-10-1998
		NO 971929 A		12-06-1997
		US 5780454 A		14-07-1998
		ZA 9509119 A		27-05-1996
WO 9524914	A 21-09-1995	AU 682600 B		09-10-1997
		AU 2228395 A		03-10-1995
		CA 2185326 A		21-09-1995
		EP 0804216 A		05-11-1997
		FI 963602 A		04-11-1996
		JP 9511501 T		18-11-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/01097

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9524914 A		NO 963814 A		14-11-1996
		US 5693617 A		02-12-1997
WO 9813061 A	02-04-1998	US 5834487 A		10-11-1998
		AU 4495997 A		17-04-1998